As scientists uncover more insights on cervical cancer, new tests and guidelines have emerged in clinical practice for cervical cancer prevention and screening.
January is Cervical Health Awareness month in the US and other parts of the world. Let’s brush up on the latest cervical cancer knowledge and share with those close to us who may be at risk.
Cervical cancer is the 2nd most frequent cancer worldwide, with 80% of cases in low and middle income countries (LMICs) where adequate screening options are not available. (1) In the United States, more than 12,000 women will be diagnosed with cervical cancer each year, and more than 4,000 women will die from cervical cancer. (2)
The digene HC2 High-Risk HPV Test has become the gold standard for HPV testing worldwide. Now, we know that ~99% of cervical cancer cases are caused by the human papillomavirus (HPV), which has over 100 genotypes. The HPV-16 and HPV-18 genotypes, often referred to as high-risk HPV types, are responsible for over 70% of cervical cancer. HPV DNA tests target hrHPV genotypes to identify women at risk for developing cervical cancer.
QIAscreen provides a menu of applications and flexibility in sample input options for HPV testing. Watch the video to find out more about the new QIAscreen test.
The QIAscreen HPV PCR Test is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA of 15 (likely) (1) high-risk HPV genotypes.
QIAscreen can bolster your Rotor-Gene Q workflow, providing a menu of applications on one instrument.
QIAscreen rounds out QIAGEN’s family of PCR-based women’s health tests on the Rotor-Gene Q instrument, which include tests for C. trachomatis, N. gonorrhoeae, and T. vaginalis. Labs can conduct a panel of women’s health tests in a more streamlined and resourceful manner to provide comprehensive insights for clinicians and patients.
1) International Agency for Research on Cancer. (2009). A review of human carcinogens. Part B: Biological Agents. Monographs 100B.
2) Snijders, P.J., Steenbergen, R.D., Heideman, D.A., Meijer, C.J. (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208, 152.
3) QIAscreen HPV PCR Test Instructions for Use. QIAGEN, 2018.
The QIAscreen HPV PCR Test is intended for in vitro diagnostic use in Europe. Self-screen B.V. is the legal manufacturer of the QIAscreen HPV PCR Test.
From 2014–2018, through the Scale-Up project, PATH and local partners provided technical assistance to governments in Nicaragua, Guatemala, Honduras and El Salvador to introduce HPV testing and improve access to screening. PATH encouraged ministry of health leadership to implement self-sampling as a primary screening strategy to enhance access and acceptability among women while overcoming infrastructure barriers. To date, almost a quarter of a million women have been screened using QIAGEN’s careHPVTM Test across the four countries.
Context and Women Screened in PATH’s Scale-Up Project, 2015-2018
|El Salvador||Honduras||Guatemala||Nicaragua||Regional (all four project countries combined)|
|Target population in project areas||132,173||448,948||496,407||141,637||1,219,165|
|Total women screened in project areas+||17,891||74,040||83,516||73,642||249,089|
|Crude incidence rate of cervical cancer in 2018 among females aged 30 to 64 years (per 100,000)*||32.7||37.4||36.5||39.3||196|
|5-year prevalence of cervical cancer among females aged 30 to 64 years*||1,133||1,502||2,561||1,236||6,432|
+Source: Ministries of Health
*Source: GLOBOCAN 2018